NAD+ dosage

NAD+ injectable dosage

Reported-use amounts for NAD+ are 50 mg per administration, 3x weekly, for 30 days. An additional reported subcutaneous range is 50–100 mg daily, without a fixed course length. This differs from intermittent injection schedules and should not be combined with an IV infusion amount.[16][17]

Direct NAD+ is the coenzyme itself, rather than the precursors NMN or NR. IV, subcutaneous, nasal and skin preparations have different concentrations and exposure patterns.[1][2][3][12][13][16]

NAD+ nasal dosage

Reported-use amounts for NAD+ are 30 mg per administration, daily, on an ongoing basis.[16]

Direct NAD+ is the coenzyme itself, rather than the precursors NMN or NR. IV, subcutaneous, nasal and skin preparations have different concentrations and exposure patterns.[14][15][3][1][2][16]

NAD+ topical dosage

Reported topical NAD+ routines use 100 mg per application once daily on an ongoing basis.[16]

Direct NAD+ is the coenzyme itself, rather than the precursors NMN or NR. IV, subcutaneous, nasal and skin preparations have different concentrations and exposure patterns.[14][15][1][2][3][16]

NAD+ intravenous dosage

Reported-use amounts for NAD+ are 750 mg per administration, as a single infusion, during a single visit. An alternative schedule uses 250–500 mg per IV infusion over 1–2 hours, one or two times weekly, without a fixed course length. This is a reported infusion pattern, separate from the documented 750 mg single-infusion exposure and from subcutaneous injection amounts.[16][17]

An NAD+ infusion requires its own dilution, infusion duration and clinical monitoring. An injectable reminder amount does not specify an IV infusion procedure.[1][2][3][16]

Frequency and timing

Morning is a listed option for subcutaneous, nasal and topical use. The listed single-infusion IV exposure spans 6 hours; other IV patterns follow their own infusion durations.[14][15][16]

Cycle length and breaks

Injectable: 30 days. Nasal: Ongoing. Topical: Ongoing. Intravenous: Single visit. Ongoing treatment does not follow a routine on/off cycle.[16]

Approval and product quality

NAD+ is not an FDA-approved drug.[4][5][6]

Side effects and long-term safety

A reliable common-adverse-effect rate, long-term safety profile, and equivalence across formulations have not been established. Direct NAD+ has limited route-matched human safety data. Product quality is a material risk for sterile injectables because FDA has documented serious reactions linked to excessive endotoxin in compounded NAD+ products.[10][11][4][5][6]

Route-specific dosing limits

Injectable NAD+ requires a properly compounded sterile product and route-specific clinical review. Reported-use injectable, nasal, and intravenous schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[4][5][6][17][16]